{"abstract":"The National Eye Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice certain of the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this notice to Connectyx Technologies Holdings Group located in Boca Raton, Florida.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2020/10/22/2020-23386.html","cfr_references":[],"citation":"85 FR 67360","comment_url":null,"comments_close_on":"2020-11-06","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before November 6, 2020 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2020-23386","effective_on":null,"end_page":67360,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2020/10/22/2020-23386.xml","html_url":"https://www.federalregister.gov/documents/2020/10/22/2020-23386/prospective-grant-of-an-exclusive-patent-license-development-of-a-direct-ocular-administered","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2020-23386?publication_date=2020-10-22","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2020-10-22/2020-23386/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":876,"last_updated":"2026-09-21 18:15:06 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2020-10-22/pdf/2020-23386.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2020-23386.pdf?1603284330","publication_date":"2020-10-22","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2020/10/22/2020-23386.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T05:13:47Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":67360,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Development of a Direct Ocular Administered Formulation of Metformin for Use in Therapeutic Treatment of Retinal Degenerative Diseases in Humans","toc_doc":"Development of a Direct Ocular Administered Formulation of Metformin for use in Therapeutic Treatment of Retinal Degenerative Diseases in Humans","toc_subject":"Prospective Grant of an Exclusive Patent License:\n","topics":[],"type":"Notice","volume":85}